Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

SBRT may boost efficacy of immunotherapy in renal cell carcinoma

Publish date:: February 21, 2020

Key clinical point: Stereotactic body radiation therapy may increase the efficacy of nivolumab and ipilimumab in metastatic renal cell carcinoma.

Major finding: The objective response rate was 56%, but this did not meet the prespecified threshold for efficacy (70%).

Study details: A single-center, phase 2 trial of 25 patients with metastatic clear-cell renal cell carcinoma.

Disclosures: The trial was funded by KidneyCAN. The presenter disclosed relationships with Bristol-Myers Squibb, which markets nivolumab and ipilimumab, as well as other companies.

Citation:

Hammers HJ et al. GUCS 2020, Abstract 614.

This Week's Must Reads

Younger adults present with more advanced esophageal adenocarcinoma,

PDAC: Tumor reduction after neoadjuvant therapy may predict postsurgical survival,

Mortality risks rise with age, infections, but not inhibitor status in persons with non-severe hemophilia A,

‘Impressive’ local control with MRI-guided brachytherapy in cervical cancer,

U.S. mothers underestimate role breastfeeding plays in curbing breast cancer,

Must Reads in Genitourinary Cancer

Study shows no link between race and mortality in clear cell RCC,

Four factors may predict better survival with cabozantinib in mRCC,

Focal radiation boost nets better outcomes in prostate cancer,

Fear of recurrence highly prevalent in RCC survivors,

Immune checkpoint inhibitors don’t increase COVID-19 incidence or mortality, studies suggest,